On this page
PPT1
palmitoyl-protein thioesterase 1
PPT1 is located on the short (p) arm of chromosome 1, at band 1p34.2. Arm ratio per GRCh38 - banding schematic.
Explore chromosome 1 in the library →Available at Jeen Health
Clinical tests that include this
Overview
PPT1 (palmitoyl-protein thioesterase 1) is located on chromosome 1 and encodes an enzyme with a fundamental role in cellular maintenance. The enzyme resides within lysosomes, the cell's recycling compartments, where it cleaves palmitate and other long-chain fatty acids from proteins destined for degradation. This depalmitoylation activity is particularly important in the nervous system, where the enzyme contributes to synaptic development and neuronal health.
The PPT1 gene is classified within UK carrier screening panels for autosomal recessive conditions. Biallelic pathogenic variants lead to enzyme deficiency, resulting in the accumulation of storage material in cells and progressive neurodegeneration. Understanding PPT1 function is essential for interpreting carrier status and the implications for infantile-onset lysosomal storage disorders.
What the gene does
Palmitoyl-protein thioesterase 1 catalyses the removal of palmitate, a 16-carbon saturated fatty acid, from cysteine residues on target proteins within the lysosomal environment. This thioesterase activity is essential for the complete degradation of palmitoylated proteins, which otherwise accumulate as incompletely processed material. The enzyme preferentially acts on proteins modified with long-chain fatty acids, facilitating their breakdown into constituent amino acids and lipids that can be recycled by the cell.
Beyond its role in lysosomal protein degradation, research suggests that palmitoyl-protein thioesterase 1 participates in synaptic maturation and maintenance. The enzyme appears to influence the development of connections between nerve cells, where effective communication depends on proper protein turnover. Loss of this enzymatic function particularly affects neurons, which have high metabolic demands and limited regenerative capacity. The precise substrates and regulatory mechanisms governing PPT1 activity continue to be areas of active investigation.
Video: Genetics 101
Chromosome location
The PPT1 gene is positioned at 1p34.2 on the short arm of chromosome 1. This chromosomal region contains multiple genes involved in neurological function and metabolic processes. The gene spans several kilobases and encodes a 306-amino-acid protein through multiple exons. The genomic organisation allows for regulated expression of the enzyme across different tissues, with particularly high levels in the central nervous system.
Protein structure
Domain architecture has not been experimentally characterised in detail for this protein. The 306-amino-acid sequence includes a signal peptide that directs the nascent protein to the endoplasmic reticulum for processing and eventual trafficking to lysosomes. Following signal peptide cleavage, the mature enzyme contains the catalytic residues necessary for thioesterase activity. The protein undergoes post-translational modifications including glycosylation, which may influence its stability and localisation within the lysosomal compartment.
Key variants
Over 65 pathogenic variants in PPT1 have been identified in individuals with CLN1 disease. These variants include missense changes, nonsense mutations, frameshift alterations, and splice-site disruptions, all resulting in reduced or absent enzyme activity. The spectrum of variants demonstrates complete loss of function as the primary disease mechanism. Certain variants show founder effects in specific populations, whilst others represent sporadic or recurrent mutational events at hotspot residues.
No pathogenic or likely-pathogenic ClinVar variants recorded yet for this gene.
Associated conditions
Biallelic pathogenic variants in PPT1 cause Batten disease (CLN1, infantile), a progressive neurodegenerative disorder classified within the neuronal ceroid lipofuscinoses. This condition typically manifests between 6 and 18 months of age with developmental regression, seizures, and vision loss. Affected children experience loss of previously acquired motor and cognitive skills, progressive blindness due to retinal degeneration, and intractable epilepsy. The disorder follows an autosomal recessive inheritance pattern, meaning both copies of PPT1 must carry pathogenic variants for the condition to develop. Carrier individuals possess one functional gene copy and do not develop symptoms.
Inheritance pattern
Conditions caused by pathogenic PPT1 variants typically follow autosomal recessive inheritance.
When both parents are carriers, each child has a 25% chance of being affected, 50% of being a carrier, and 25% of being unaffected.
UK clinical status
PPT1 holds green classification across multiple NHS Genomic Medicine Service panels, reflecting strong evidence for gene-disease association. The gene appears on the DDG2P database and specialist panels including Early onset or syndromic epilepsy, Intellectual disability, Likely inborn error of metabolism, Lysosomal storage disorder, Neuronal ceroid lipofuscinosis, Retinal disorders, and Undiagnosed metabolic disorders. This extensive panel representation indicates that PPT1 testing is considered clinically appropriate for individuals presenting with early-onset neurological decline, developmental regression, epilepsy, or features suggestive of lysosomal storage pathology.
Sources: NHS GMS PanelApp · Genomics England PanelApp · NHS National Genomic Test Directory
Frequently asked questions
What does it mean to be a carrier of a PPT1 variant?
Carriers possess one pathogenic PPT1 variant and one functional gene copy, producing sufficient enzyme for normal cellular function. Carriers do not develop symptoms of CLN1 disease. If both reproductive partners are carriers, each pregnancy has a 25% chance of inheriting two pathogenic variants and being affected.
How does PPT1 deficiency cause neurological symptoms?
Absence of functional palmitoyl-protein thioesterase 1 prevents proper degradation of palmitoylated proteins within lysosomes. This leads to accumulation of storage material, particularly in neurons, disrupting cellular function and ultimately causing progressive cell death. The brain's high metabolic activity and limited capacity for regeneration make it particularly vulnerable to this enzyme deficiency.
Is PPT1 testing available through the NHS?
PPT1 analysis is available through NHS clinical genetics services for individuals with features suggestive of neuronal ceroid lipofuscinosis or related lysosomal storage disorders. Carrier screening for reproductive planning may be accessed through genetic counselling services, particularly for individuals with a family history of CLN1 disease or known carrier status in their family.
References
- Kollmann K, Uusi-Rauva K, Scifo E. Cell biology and function of neuronal ceroid lipofuscinosis-related proteins. Biochimica et biophysica acta. 2013. PMID: 23402926
- Hawkins-Salsbury JA, Cooper JD, Sands MS. Pathogenesis and therapies for infantile neuronal ceroid lipofuscinosis (infantile CLN1 disease). Biochimica et biophysica acta. 2013. PMID: 23747979
- Kousi M, Lehesjoki AE, Mole SE. Update of the mutation spectrum and clinical correlations of over 360 mutations in eight genes that underlie the neuronal ceroid lipofuscinoses. Human mutation. 2012. PMID: 21990111
- Jalanko A, Braulke T. Neuronal ceroid lipofuscinoses. Biochimica et biophysica acta. 2009. PMID: 19084560
- Simonati A, Tessa A, Bernardina BD. Variant late infantile neuronal ceroid lipofuscinosis because of CLN1 mutations. Pediatric neurology. 2009. PMID: 19302939
- Kim SJ, Zhang Z, Sarkar C. Palmitoyl protein thioesterase-1 deficiency impairs synaptic vesicle recycling at nerve terminals, contributing to neuropathology in humans and mice. The Journal of clinical investigation. 2008. PMID: 18704195
- Ramadan H, Al-Din AS, Ismail A. Adult neuronal ceroid lipofuscinosis caused by deficiency in palmitoyl protein thioesterase 1. Neurology. 2007. PMID: 17261688
- Das AK, Lu JY, Hofmann SL. Biochemical analysis of mutations in palmitoyl-protein thioesterase causing infantile and late-onset forms of neuronal ceroid lipofuscinosis. Human molecular genetics. 2001. PMID: 11440996